pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,047 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT776Endpoints580BioPharma Dive223onclive165Fierce Biotech54BioSpace52raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • STAT+: What’s changed since the last major Ebola outbreak
    A suppressed federal alcohol report, an "inevitable development" for wearables data, and more health news from Morning Rounds
    STAT · 1mo ago↗ source
  • Opinion: Ending animal testing could set back xenotransplantation just as the field is poised for a breakthrough
    “Innovations like xenotransplantation would never have reached clinical trials without animal experimentation,” writes transplant surgeon Joshua Mezrich.
    STAT · 1mo ago↗ source
  • STAT+: Wearables, and the flood of data they generate, inch closer to entering the clinic
    Wearables generate a lot of health data, but it exists outside the clinic for the most part. New moves from Oura and Whoop may change that.
    STAT
← prev
page 20 of 42
next →
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
· 1mo ago
↗ source
  • Opinion: Why STAT is sticking with ‘health care’ as two words
    Is it “health care” or “healthcare”? STAT readers had strong feelings.
    STAT · 1mo ago↗ source
  • STAT+: Trump’s health care affordability czar touts Medicaid cuts to hospital leaders
    Hospital execs say they're working to mitigate the impacts of the looming cuts.
    STAT · 1mo ago↗ source
  • A leader of the 2014 U.S. Ebola response compares then to now
    As the world deals with an outbreak of Ebola that has no known cure, Susan Reichle, who last year co-founded Aid Transition Alliance to support former USAID professionals, discusses the…
    STAT · 1mo ago↗ source
  • STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
    GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.
    STAT · 1mo ago↗ source
  • Alcohol study discarded by Trump officials is published in scientific journal
    A government-commissioned study had been meant to inform new dietary guidelines, and found risks associated with even light drinking.
    STAT · 1mo ago↗ source
  • Health workers at the epicenter of Congo’s Ebola outbreak labor with little pay or rest
    Health workers at the epicenter of Congo's Ebola outbreak are laboring with little pay or rest.
    STAT · 1mo ago↗ source
  • STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
    AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.
    STAT · 1mo ago↗ source
  • STAT+: UnitedHealthcare’s lactation billing feud, and fake strokes
    The biggest U.S. health insurer is changing how it pays for lactation counseling, and it could cut payment for many providers.
    STAT · 1mo ago↗ source
  • STAT+: Novo underwhelmed by drug it once fought Pfizer for
    Revolution and Tango yield promising cancer results, Incyte buys bleeding disorder drug, and more biotech news
    STAT · 1mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more
    Lilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug retatrutide
    STAT · 1mo ago↗ source
  • STAT+: J&J spends $1 billion to enter KRAS race for cancer treatments
    Johnson & Johnson said it will purchase the startup Firefly Bio for $1 billion in an effort to expand its work in the suddenly buzzy field of KRAS inhibitors.
    STAT · 1mo ago↗ source
  • Major readouts from the annual diabetes conference
    Why "Schedule F" matters, the Ebola outbreak response, and more health news from Morning Rounds
    STAT · 1mo ago↗ source
  • STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate
    A combination of pancreatic cancer drugs from Tango Therapeutics and Revolution Medicines led to a strong response rate in an early-stage trial.
    STAT · 1mo ago↗ source
  • When it’s time to save a limb, novel clinic meets unhoused people where they are
    Unmet vascular needs can lead to limb loss among unhoused patients. An unusual Massachusetts General Hospital program meets patients where they are.
    STAT · 1mo ago↗ source
  • Opinion: American horses are obese, too
    “American horses are getting sick in ways that look remarkably familiar,” writes Joshua Moen.
    STAT · 1mo ago↗ source
  • Opinion: $2 million gene therapy cures require a financing model
    “We do not lack cures. We lack the infrastructure to pay for and deliver them,” writes William Padula.
    STAT · 1mo ago↗ source
  • STAT+: Competition for obesity drugs, clinical blind spots, and more news from ADA
    You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference.
    STAT · 1mo ago↗ source
  • STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
    Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.
    STAT · 1mo ago↗ source
  • STAT+: Triple hormone receptors, a monthly obesity drug, and a bittersweet ending
    You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference in New Orleans.
    STAT · 1mo ago↗ source
  • STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug
    Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.
    STAT · 1mo ago↗ source
  • STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential
    Detailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly.
    STAT · 1mo ago↗ source
  • Opinion: How the Amish think about vaccines, health care costs, and much more
    There may be nearly 2 million Amish Americans by 2075. That has large public health implications.
    STAT · 1mo ago↗ source